

ASX Announcement

9 September 2025

OncoSil Announces New Non-Executive Chairman

Melbourne, Australia – 9 September 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), today announces two strategic changes to its current Board structure.

Dr Thomas Duthy, who joined the OncoSil Medical Board as a Non-Executive Director on 11 July 2025, has now been appointed as Non-Executive Chairman of the Company, effective 1 October 2025.

Dr Duthy is a highly regarded healthcare senior executive. In a career now extending beyond 20 years, he has held key positions in a number of healthcare and technology companies. He is the Founder and Director of Nemean Group, a corporate advisory firm serving healthcare and technology companies, and has been involved in numerous successful M&A transactions.

Dr Duthy has a track record of success in the oncology device setting - given his previous position as Head of Corporate Development and Investor Relations at Sirtex Medical (ASX:SRX), where he played a key role in its \$1.9 billion all-cash acquisition.

Dr Duthy replaces the current Chairman of OncoSil Medical, Mr Doug Cubbin, who has held this position since August 2023. To help facilitate a smooth transition in Dr Duthy’s elevation to Chairman, Mr Cubbin will remain in the role until 1 October 2025. Once this changeover period is complete, Mr Cubbin will become a Non-Executive Director on OncoSil Medical’s Board of Directors. This ensures the Company retains the skills of Mr Cubbin, who has over three decades’ experience in senior executive roles across varied industries and a deep understanding of OncoSil Medical’s business operations.

Incoming OncoSil Medical Chairman Dr Thomas Duthy, said:

“I was thrilled to join the OncoSil Medical Board of Directors back in July 2025. The OncoSil™ device is a valuable treatment option for patients with unresectable locally advanced pancreatic cancer, where new treatments are desperately needed to increase patient survival without the side-effects traditionally associated with systemic chemotherapy. I am genuinely excited to take on the extra responsibilities accompanying the Chairman role as we grow our penetration in existing markets, enter new markets and generate further important clinical data to support clinician adoption and improve market access. I personally want to thank Doug for his hard work as Chair of OncoSil Medical over the past two years and look forward to working with him in his capacity as a Non-Executive Director of the Company.”

Outgoing OncoSil Medical Chairman Mr Doug Cubbin, said:

“It has been an honour to have been OncoSil Medical’s Chairman over the past couple of years. This period has not just seen the Company successfully advance the development of its innovative OncoSil™ device. It has also seen OncoSil Medical tick off a host of the milestones required to make the device available to medical professionals operating in healthcare facilities located across key target regions including the US, EU and Middle East. Along with the rest of OncoSil Medical’s leadership team, I now look forward to playing a role in further progressing the Company’s development strategy.”

Under the terms of the appointment, Dr Duthy will receive a Chair fee of \$150,000 + GST per annum, of which approximately 41% will be received in OncoSil shares subject to shareholder approval at the Company’s 2025 Annual General Meeting (AGM) at \$1.50 per share representing 100% of his entire first 12 month Non-Executive Director fee, consistent with the terms of his appointment on 11 July 2025, with a 12 month voluntary escrow.

In addition, Ms Lelde Smits, Non-Executive Director of OncoSil Medical has requested and received Board approval to receive OncoSil Medical shares *in lieu* of Non-Executive Director fees commencing 1 October 2025 at a price of \$1.50 per share, also subject to shareholder approval at the 2025 AGM and a voluntary 12 month escrow.

Ends.

Authorisation & Additional Information

This announcement was authorised by the Board of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Tim Luscombe & Mr. David Wood Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	--	---

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Greece, Turkey, and Israel.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>